Ferring Pharmaceuticals and North Zealand University Hospital mark first milestone in innovative IBD collaboration
-Ferring Pharmaceuticals and North Zealand University Hospital (Nordsjællands Hospital) yesterday formally inaugurated…
Ferring Pharmaceuticals Acquires Exclusive Licensing Rights to Condoliase from Seikagaku Corporation
-Ferring Pharmaceuticals announced today that it has signed an agreement with Seikagaku Corporation granting Ferring the exclusive worldwide rights…
Ferring announces Phase 3 data for investigational human recombinant FSH with individualised dosing regimen at the 32nd Annual Meeting of ESHRE®
-Data from the Phase 3 ESTHER trials (Evidence-based Stimulation Trial with Human recombinant follicle-stimulating hormone…
Ferring Pharmaceuticals announces approval of new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label in MRP countries in Europe
-Ferring Pharmaceuticals has successfully finalised a Mutual…
Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program
-The Ferring Innovation Grants Program, which is now open for applications, has been significantly expanded as part of Ferring’s continued commitment to investing in research and development…
